PoreWise One finding · Human trial · 2026
Study title
Moisturizer Containing Centella Asiatica Extract, Ceramide NP, and Panthenol for Erythema and Skin Barrier in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial
- Kind of evidence
- Human trial 2026 · 75 people · patients with erythematotelangiectatic rosasma · PMID 42876425
- Measured outcome
- Skin effect
- Year
- 2026
- Who was studied
- 75 patients with erythematotelangiectatic rosasma
- Sample size
- 75
- Measured outcome
- In a randomized controlled trial of 75 patients with erythematotelangiectatic rosacea, a moisturizer containing Centella asiatica extract, ceramide NP and panthenol produced greater improvements in facial redness and barrier measures than the control group at day 28.
- Certainty
- Moderate
- Who was measured
- Adults with erythematotelangiectatic rosacea using the combination moisturizer twice daily for 28 days, alongside oral minocycline.
- Study limits
- Centella asiatica was one of three actives in the moisturizer; all adverse events were mild and self-limiting.
Where it comes from
- Moisturizer Containing Centella Asiatica Extract, Ceramide NP, and Panthenol for Erythema and Skin Barrier in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial
Published by Skin Research and Technology (Jiang X, Luo H, He X, et al.) · Last checked 2026-10-29
Ingredients it was measured on
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectThe Effectiveness and Safety of a Skin Care Product With Centella asiatica Leaf Extract, Ceramide NP, and Panthenol in Subjects With Sensitive Skin: A Prospective, Observational Study
In 88 women with sensitive skin, a face cream containing Centella asiatica leaf extract, ceramide NP and panthenol lowered the SS-10 symptom score by 66% at week 2 and 76% at week 4, with irritation, tautness, itching and redness all significantly reduced.
Human trial · 2025 · 88 people · women with sensitive skin · Chinese women with sensitive skin applying the cream to the whole face, followed up at day 2, weeks 1, 2 and 4. · Observational and self-controlled.
- Skin effectTopical Application of Centella asiatica in Wound Healing: Recent Insights into Mechanisms and Clinical Efficacy
A 2024 review summarises that Centella asiatica's active compounds (asiaticoside, madecassoside, asiatic acid, madecassic acid) support collagen synthesis, moderate inflammation and provide antioxidant protection, and that clinical studies have explored topical Centella asiatica for wound healing and skin recovery.
Review article · 2024 · Topical Centella asiatica extracts and their isolated compounds. · This is a review.
- Skin effectDoxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea
Low-dose (anti-inflammatory, sub-antimicrobial) oral doxycycline 40 mg once daily was significantly more effective than placebo at reducing inflammatory lesions in rosacea across two pivotal randomized, double-blind, placebo-controlled, multicenter trials (16 weeks). The 40 mg dose works as an anti-inflammatory.
Review article · 2010 · Adults with rosacea in two pivotal multicenter trials · Oral prescription treatment for inflammatory rosacea. A medicine. · The cited source is a published drug evaluation that summarizes two pivotal trials. Like the ivermectin evidence here. Low-dose doxycycline is anti-inflammatory and sub-antimicrobial, oral antibiotics carry their own considerations.
- Skin effectSuperiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial
In moderate-to-severe papulopustular rosacea, once-daily ivermectin 1% cream reduced inflammatory lesion counts by 83.0% from baseline at 16 weeks versus 73.7% for twice-daily metronidazole 0.75% cream (P<0.001, 962 participants), and more subjects reached 'clear' or 'almost clear' on the investigator's global assessment (84.9% vs 75.4%, P<0.001).
Human trial · 2015 · 962 people · adults with moderate-to-severe papulopustular rosacea · Prescription topical treatment for papulopustular rosacea. This is a medicine. · A randomized trial of a marketed drug against another prescription drug. It supports ivermectin as a rosacea treatment. Funding came from the drug's developer (Ivermectin Phase III study group).
- Skin effectNiacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea
A facial moisturiser containing niacinamide improved stratum corneum barrier function and skin hydration, measured instrumentally, in people with rosacea over four weeks of twice-daily use.
Human trial · 2005 · 50 people · Adults with rosacea · A leave-on facial moisturiser, applied twice daily for four weeks, in adults with rosacea. · The tested article was a finished moisturiser. Fifty participants, one centre, four weeks. The study measured barrier function and hydration.